PXD048002

PXD048002 is an original dataset announced via ProteomeXchange.

Title	Circulating extracellular vesicles as biomarkers to monitor response to Multiple Sclerosis therapy.
Description	In the last two decades, several disease-modifying treatments (DMTs) have been developed for MS. These therapies are based on the modulation of the immune system and the aim to reduce the disease activity. However, as the natural course of the disease is unpredictable, the benefit of each treatment in each individual patient is still unknown and clinical decisions are very complicated. Some patients initiate treatment but continue with relapses, new lesions in the central nervous system, or show worsening disability. When this occurs, the response of the treatment is considered suboptimal and has to be switched to a more effective treatment, albeit generally with a higher risk of serious adverse effects. Currently, these decisions are made on a case-by-case basis when the lesions in the CNS and the increase in disability have occurred. This is likely due to multiple factors, including the absence of highly predictive, widely used treatment response biomarkers with reasonable sensitivity and specificity that step over the disease heterogeneity and that can be applied in real-life clinical practice. As a result, a high percentage of MS patients do not present adequate control of their disease activity while receiving DMT. In this context, a biomarker that anticipates treatment response or predicts treatment failure would help to make the change before irreversible injury occurs. We aim to analyse whether proteins and miRNAs derived from patients' circulating EVs could provide relevant information about the patient's response to treatment. To build on this, we assessed EV levels, size, microRNA, and protein content from neurons, oligodendrocytes, B and T lymphocytes, pre- and 3 months post-treatment initiation, and correlated with therapeutic response over 12 months in MS patients. Treatment response treatment was evaluated using ‘no evidence of disease activity’ (NEDA5) composite that includes the following clinical parameters: clinical relapses, new lesions on MRI, motor and cognitive disability progression and brain atrophy.
HostingRepository	PRIDE
AnnounceDate	2025-05-06
AnnouncementXML	Submission_2025-05-06_12:29:04.992.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Susana Bravo
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	No PTMs are included in the dataset
Instrument	TripleTOF 6600

Revision	Datetime	Status	ChangeLog Entry
0	2023-12-20 05:53:06	ID requested
⏵ 1	2025-05-06 12:29:05	announced

10.3390/ijms251910761;

Torres Iglesias G, L, ó, pez-Molina M, Botella L, Laso-Garc, í, a F, Chamorro B, Fern, á, ndez-Fournier M, Puertas I, Bravo SB, Alonso-L, ó, pez E, D, í, ez-Tejedor E, Guti, é, rrez-Fern, á, ndez M, Otero-Ortega L, Differential Protein Expression in Extracellular Vesicles Defines Treatment Responders and Non-Responders in Multiple Sclerosis. Int J Mol Sci, 25(19):(2024) [pubmed]

submitter keyword: microRNAs, proteomics, treatment response, extracellular vesicles,Biomarkers, multiple sclerosis

Susana Bravo
contact affiliation	Instituto de Investigaciones Sanitarias de Santiago de Compostela
contact email	Sbbravo@gmail.com
lab head
Susana Bravo
contact affiliation	FIDIS
contact email	sbbravo@gmail.com
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD048002

PRIDE project URI

• PRIDE
  1. PXD048002
     1. Label: PRIDE project
     2. Name: Circulating extracellular vesicles as biomarkers to monitor response to Multiple Sclerosis therapy.